GENOWAY SA (ALGEN.PA) Fundamental Analysis & Valuation

EPA:ALGEN • FR0004053510

Current stock price

2.44 EUR
-0.01 (-0.41%)
Last:

This ALGEN.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. ALGEN.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALGEN was profitable.
  • In the past year ALGEN has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: ALGEN reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
ALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

  • The Return On Assets of ALGEN (3.31%) is better than 77.22% of its industry peers.
  • With a decent Return On Equity value of 7.00%, ALGEN is doing good in the industry, outperforming 78.48% of the companies in the same industry.
  • ALGEN has a better Return On Invested Capital (3.17%) than 74.68% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ALGEN is significantly below the industry average of 11.35%.
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROIC 3.17%
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ALGEN.PA Yearly ROA, ROE, ROICALGEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • With a decent Profit Margin value of 6.14%, ALGEN is doing good in the industry, outperforming 74.68% of the companies in the same industry.
  • ALGEN has a better Operating Margin (5.97%) than 74.68% of its industry peers.
  • ALGEN's Gross Margin of 94.91% is amongst the best of the industry. ALGEN outperforms 87.34% of its industry peers.
  • In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
Industry RankSector Rank
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
ALGEN.PA Yearly Profit, Operating, Gross MarginsALGEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ALGEN.PA Health Analysis

2.1 Basic Checks

  • ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for ALGEN has been reduced compared to 1 year ago.
  • ALGEN has more shares outstanding than it did 5 years ago.
  • ALGEN has a better debt/assets ratio than last year.
ALGEN.PA Yearly Shares OutstandingALGEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALGEN.PA Yearly Total Debt VS Total AssetsALGEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • ALGEN has an Altman-Z score of 1.97. This is not the best score and indicates that ALGEN is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ALGEN has a Altman-Z score of 1.97. This is comparable to the rest of the industry: ALGEN outperforms 55.70% of its industry peers.
  • A Debt/Equity ratio of 0.71 indicates that ALGEN is somewhat dependend on debt financing.
  • ALGEN has a Debt to Equity ratio (0.71) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Altman-Z 1.97
ROIC/WACC0.43
WACC7.35%
ALGEN.PA Yearly LT Debt VS Equity VS FCFALGEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

  • ALGEN has a Current Ratio of 2.41. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.41, ALGEN is in line with its industry, outperforming 49.37% of the companies in the same industry.
  • A Quick Ratio of 2.21 indicates that ALGEN has no problem at all paying its short term obligations.
  • ALGEN has a Quick ratio (2.21) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.21
ALGEN.PA Yearly Current Assets VS Current LiabilitesALGEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ALGEN.PA Growth Analysis

3.1 Past

  • ALGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.46%.
  • Looking at the last year, ALGEN shows a decrease in Revenue. The Revenue has decreased by -2.21% in the last year.
  • Measured over the past years, ALGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.46% on average per year.
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%

3.2 Future

  • ALGEN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by 0.00% yearly.
  • Based on estimates for the next years, ALGEN will show a quite strong growth in Revenue. The Revenue will grow by 11.17% on average per year.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-11.76%
Revenue Next 2Y0.63%
Revenue Next 3Y11.17%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALGEN.PA Yearly Revenue VS EstimatesALGEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
ALGEN.PA Yearly EPS VS EstimatesALGEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2023 2024 2027 0.05 0.1 0.15 0.2

More info and screens

Find the best growth stocksShow best growing peers

2

4. ALGEN.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 16.27 indicates a correct valuation of ALGEN.
  • 91.14% of the companies in the same industry are more expensive than ALGEN, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 26.78. ALGEN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 16.27
Fwd PE N/A
ALGEN.PA Price Earnings VS Forward Price EarningsALGEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALGEN is valued cheaply inside the industry as 91.14% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.06
ALGEN.PA Per share dataALGEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALGEN.PA Dividend Analysis

5.1 Amount

  • No dividends for ALGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALGEN.PA Fundamentals: All Metrics, Ratios and Statistics

GENOWAY SA

EPA:ALGEN (4/10/2026, 7:00:00 PM)

2.44

-0.01 (-0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners7.76%
Ins Owner ChangeN/A
Market Cap30.99M
Revenue(TTM)20.95M
Net Income(TTM)1.29M
Analysts86.67
Price Target4.49 (84.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25.42%
PT rev (3m)-25.42%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.98%
Valuation
Industry RankSector Rank
PE 16.27
Fwd PE N/A
P/S 1.48
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 2.5
EV/EBITDA 10.06
EPS(TTM)0.15
EY6.15%
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS1.65
BVpS1.45
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.21
Profitability
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROCE 3.94%
ROIC 3.17%
ROICexc 3.17%
ROICexgc 3.91%
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
FCFM N/A
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Debt/EBITDA 2.88
Cap/Depr 297.91%
Cap/Sales 46.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.21
Altman-Z 1.97
F-Score3
WACC7.35%
ROIC/WACC0.43
Cap/Depr(3y)64.02%
Cap/Depr(5y)125.45%
Cap/Sales(3y)10.32%
Cap/Sales(5y)17.64%
Profit Quality(3y)100.54%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
Revenue Next Year-11.76%
Revenue Next 2Y0.63%
Revenue Next 3Y11.17%
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year190%
EBIT Next 3Y73.25%
EBIT Next 5YN/A
FCF growth 1Y-380.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.89%
OCF growth 3YN/A
OCF growth 5YN/A

GENOWAY SA / ALGEN.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GENOWAY SA?

ChartMill assigns a fundamental rating of 3 / 10 to ALGEN.PA.


What is the valuation status of GENOWAY SA (ALGEN.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Overvalued.


Can you provide the profitability details for GENOWAY SA?

GENOWAY SA (ALGEN.PA) has a profitability rating of 4 / 10.


How financially healthy is GENOWAY SA?

The financial health rating of GENOWAY SA (ALGEN.PA) is 4 / 10.


What is the expected EPS growth for GENOWAY SA (ALGEN.PA) stock?

The Earnings per Share (EPS) of GENOWAY SA (ALGEN.PA) is expected to decline by -100% in the next year.